ADXN: Rasio kapitalisasi pasar marang pendapatan Addex Therapeutics Ltd.
The rise in the Addex Therapeutics (ADXN) share price is driven by breakthroughs in Parkinson's disease therapy and patents. A reliable raw material supplier network ensures the continuity of testing. The company's average P/S reflects the business valuation trend, with the indicator currently standing at 56.40. The financial model relies on grants and payments from global pharma partners for the development of innovative small molecules.
Rincian metrik lan analitis perusahaan Addex Therapeutics, Ltd. (ADXN)
- kuotasi lan prakiraan analis:
- informasi kapitalisasi pasar:
- indikator kapitalisasi buku:
- statistik kawajiban utang lan likuiditas:
Total Utang marang Modal Addex Therapeutics|ADXN - Utang jangka dawa marang ekuitas|Kewajiban jangka cendhak marang ekuitas Addex|ADXN - Gunggung utang perusahaan|Utang-utang marang nilai buku Addex Therapeutics, Ltd.|ADXN - Kewajiban jangka dawa perusahaan|Utang jangka cendhak perusahaan Addex Therapeutics|Rasio likuiditas perantara addextherapeutics.com
- data bathi lan kelipatan valuasi:
ADXN - Bathi resik|Prakiraan bathi perusahaan Addex Therapeutics|ADXN - Pangali P/E|Prakiraan rega marang bathi Addex Therapeutics Ltd.|ADXN - Rasio rega marang bathi tumrap wutah|Rasio total nilai perusahaan marang bathi operasional sadurunge panyusutan Addex Therapeutics, Ltd.|ADXN - Bathi operasional EBITDA|Bathi resik saben saham (EPS TTM) Addex Therapeutics|ADXN - Bathi resik saben saham (EPS TTM)|Wutah bathi saben saham taun-ka-taun sajrone 12 wulan pungkasan addextherapeutics.com|ADXN - Wutah bathi resik saben saham ing taun iki|Proyeksi kacepetan wutah bathi saben saham kanggo taun ngarep Addex Therapeutics
- data total pendapatan lan volume dodolan:
Analisis umum perusahaan:ADXN - addextherapeutics.com
To build a high-quality portfolio, I utilize the P/S ratio, which determines the market value of a single dollar of revenue, allowing for an assessment of the business premium regardless of current profitability. In the case of Addex Therapeutics (ADXN), which focuses on R&D and the search for strategic partners, the P/S history reflects market expectations for the commercialization of allosteric modulators relative to actual sales volumes.
Karo sapa Addex Therapeutics saingan
Kapitalisasi marang volume dodolan BIIB|Multiplikator P/S NBIX (Neurocrine Biosciences, Inc.)|Rasio kapitalisasi pasar marang pendapatan RGC|Axsome Therapeutics Inc - Multiplikator P/S|Rega marang dodolan ACADIA Corp|Xenon Pharmaceuticals (XENE) - Rasio rega marang pendapatan|vikingtherapeutics.com - Rasio kapitalisasi pasar marang pendapatan|SUPN (Supernus) - Multiplikator P/S|Multiplikator P/S Catalyst Pharma|Rasio rega marang pendapatan Denali Therapeutics Inc (DNLI)|HRMY: Rasio rega marang dodolan|Multiplikator P/S BHVN (Biohaven Ltd.)|amylyx.com (AMLX) - Rega marang dodolan|TRVI: Kapitalisasi marang pendapatan|PRAX - Multiplikator P/S|AVXL (Anavex Corp) - Kapitalisasi marang pendapatan|CBLL: Kapitalisasi marang volume dodolan|PRTA (Prothena Biosciences) - Multiplikator P/S|Alector Therapeutics (ALEC) - Koefisien rega marang pendapatan|Multiplikator P/S ANNX|Kapitalisasi marang pendapatan omeros.com OMER|Rasio rega marang pendapatan Neurogene Corp NGNE|Koefisien rega marang pendapatan AC Immune Inc (ACIU)|Voyager Therapeutics - Multiplikator P/S|NMRA - Multiplikator P/S|SCLX: Multiplikator P/S|Rasio kapitalisasi marang pendapatan TVGN|Kapitalisasi marang pendapatan ACOG|Rasio kapitalisasi marang pendapatan CGTX (Cognition Therapeutics Inc.)|Rasio rega marang pendapatan Inhibikase Therapeutics (IKT)|cassavasciences.com - Rasio kapitalisasi marang pendapatan|Rasio rega marang pendapatan Assertio ASRT|COYA: Rasio kapitalisasi marang pendapatan|VistaGen Therapeutics Inc - Multiplikator P/S|Rega marang dodolan Ovid Therapeutics Inc.|ABOS (Acumen Pharmaceuticals) - Kapitalisasi marang pendapatan|cervomed.com (CRVO) - Multiplikator P/S|Rasio rega marang pendapatan Alterity Therapeutics Ltd.|CLNN: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan PepGen Inc. (PEPG)|JUNS - Rega marang dodolan|Multiplikator P/S RLMD (Relmada Therapeutics)|Multiplikator P/S annovisbio.com ANVS|Grace Tx - Multiplikator P/S|AIFF (Firefly Neuroscience, Inc.) - Rasio kapitalisasi marang pendapatan|KLTO: Multiplikator P/S|Rasio kapitalisasi marang pendapatan NRSN|RVPH (Reviva Pharmaceuticals) - Multiplikator P/S|Rega marang dodolan MetaVia, Inc. MTVA|Kapitalisasi marang pendapatan NRXS (NeurAxis)|heliusmedical.com - Rasio kapitalisasi marang pendapatan|Passage Bio - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan NEUP|NERV: Kapitalisasi marang pendapatan|athira.com - Kapitalisasi marang volume dodolan|ALZN: Multiplikator P/S|Cyclerion Therapeutics, Inc. - Rasio kapitalisasi pasar marang pendapatan|PTIX (Protagenic Therapeutics Inc.) - Multiplikator P/S|Rega marang dodolan Pasithea KTTA|Rasio rega marang pendapatan Cortigent, Inc. (CRGT)|ATXI (avenuetx.com) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S BCLI (BrainStorm Cell Therapeutics)|Multiplikator P/S Cara Therapeutics Inc. CARA|CHRO - Rasio rega marang pendapatan|Rasio rega marang dodolan ELYM|ITCI: Multiplikator P/S|Rega marang dodolan longboardpharma.com (LBPH)|Kapitalisasi marang pendapatan MRNS|Multiplikator P/S NKGen Biotech Inc|Kapitalisasi marang pendapatan NRBO (NeuroBo)|Kapitalisasi marang volume dodolan SAGE|Multiplikator P/S SNPX (Synaptogenix, Inc.)|Koefisien rega marang pendapatan trevena.com (TRVN)|Vigil Neuro - Multiplikator P/S|anewmeds.com (WENA) - Kapitalisasi marang pendapatan|Cerevel (CERE) - Rasio rega marang pendapatan
